Novo Nordisk Surges as JPMorgan Upgrades Sales Forecast for GLP-1 Obesity Drug Pipeline

The Quick Take

• Novo Nordisk (NVO) stock surged after JPMorgan upgraded its sales forecast for the company's GLP-1 obesity drug portfolio
• JPMorgan's revised forecast reflects expanded insurance coverage and accelerating patient adoption of semaglutide in the US market
• Novo Nordisk faces competition from Eli Lilly (LLY) but maintains first-mover advantage in GLP-1 manufacturing scale

Novo Nordisk's shares rose following JPMorgan's decision to upgrade its sales forecast for the Danish pharmaceutical company's GLP-1 receptor agonist portfolio, centred on semaglutide sold under the brand names Ozempic (diabetes) and Wegovy (obesity). JPMorgan's analyst revision appears to reflect improving expectations for insurance coverage expansion and patient retention rates that exceed earlier market assumptions. Novo Nordisk has benefited from the explosive consumer demand for GLP-1 treatments that has made Ozempic and Wegovy among the most-discussed prescription drugs in the world.

The JPMorgan upgrade reinforces the bifurcation in the global pharmaceutical sector between companies with GLP-1 exposure and those without. Eli Lilly, with its competing tirzepatide (Mounjaro/Zepbound) products, remains Novo Nordisk's primary competitor in a market that several investment banks have projected will reach $150 billion in annual global revenues by 2030. The upgrade's market impact also reflects broader sector sentiment: pharmacy benefit managers and US healthcare payers are grappling with the fiscal implications of covering obesity drugs at scale, and any positive signal on coverage expansion benefits both Novo and Lilly simultaneously.

Investors should track Novo Nordisk's next quarterly results for actual Wegovy and Ozempic prescription volume data, which will either confirm or challenge JPMorgan's upgraded trajectory. The key manufacturing constraint — Novo has struggled at points to meet surging demand — is the watch point that could delay forecast realisation. The macro variable is US insurance coverage policy: a CMS decision to cover GLP-1 drugs under Medicare for obesity would be the single largest demand catalyst remaining for the drug class.

Synthesized from 1 source.